Liliane Spencer Bittencourt Brochier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Liliane Spencer Bittencourt Brochier has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
- Cristianne Maria Famer Rocha
Universidade Federal do Rio Grande do Sul
3 shared publications - Adriano José Pereira
Hospital Israelita Albert Einstein - São Paulo (SP), Brazil
2 shared publications - Alexandre Prehn Zavascki
Infectious Diseases and Infection Control Service, Hospital Moinhos de Vento, Porto Alegre, Brazil
2 shared publications - Andre Celestino Kalil
Division of Infectious Diseases, Department of Internal Medicine, University of Nebraska Medical Center , Omaha, NE
2 shared publications - Beatriz Arns
Infectious Diseases and Infection Control Service, Hospital Moinhos de Vento , 90560-032 Porto Alegre
2 shared publications - Bruna Silveira da Rosa
Ministério da Saúde, Brazil
2 shared publications
Latest Publications
- Open Access
- 18 December 2024
- Published by Springer Nature in Critical Care
- Vol. 28 (1) , 1-12
Seven versus 14 days of antimicrobial therapy for severe multidrug-resistant Gram-negative bacterial infections in intensive care unit patients (OPTIMISE): a randomised, open-label, non-inferiority clinical trial
Shorter courses of antimicrobial therapy have been shown to be non-inferior to longer durations for the management of several infections. However, data on critically ill patients with severe infections by multidrug-resistant Gram-negative bacteria (MDR-GNB) are scarce. In the duratiOn of theraPy in severe infecTIons by MultIdrug-reSistant gram-nEgative bacteria (OPTIMISE) trial, we assessed the non-inferiority of 7-day versus 14-day antimicrobial therapy for patients with intensive care unit (ICU)-acquired severe infections by MDR-GNB. This was a randomised multicenter, open-label, parallel controlled, non-inferiority trial. Adult patients with severe infections by MDR-GNB initiated ≥ 48 h of ICU admission were eligible if they were hemodynamically stable and without fever > 48 h on the 7th day of appropriate antimicrobial therapy. Patients were 1:1 randomised to discontinue antimicrobial therapy on the 7th (± 1) day or to continue for a total of 14 (± 1) days. The primary outcome was clinical failure, defined as death or relapse of infection within 28 days of randomisation. An upper edge of the two-tailed 95% confidence interval (CI) of the delta between the clinical failure rate in the 7- and the 14-day lower than 10% in both intention-to-treat (ITT) and per protocol (PP) analyses was set as the non-inferiority criteria. A total of 106 patients composed the ITT population: 59 and 47 allocated to 7- and 14-day groups, respectively. The PP population included 75 patients: 47 and 28 in the 7- and 14-day groups, respectively. Clinical failure occurred in 42.4% and 44.7% of the ITT population in 7- and 14-day groups, respectively, (risk difference (RD) − 2.3, 95%CI − 21.3 to 16.7), and in 46.8% and 50.0% of the PP population in 7- and 14-day groups, respectively (RD − 3.2, 95%CI − 26.6 to 20.2). Most infections were of the respiratory tract (73/68.9%) and caused by carbapenem-resistant Enterobacterales (42/39.6%). The study was interrupted before reaching planned sample size due to low recruitment rate. The OPTIMISE trial could not determine the non-inferiority of 7-day compared to 14-day therapy for severe infections caused by MDR-GNB due to early termination related to the low recruitment rate. Trial registration: NCT05210387 on January 13, 2022.
- 18 December 2024
- Published by Springer Nature in Critical Care
- Vol. 28 (1) , 1-12
Open AccessSeven versus 14 days of antimicrobial therapy for severe multidrug-resistant Gram-negative bacterial infections in intensive care unit patients (OPTIMISE): a randomised, open-label, non-inferiority clinical trial
Shorter courses of antimicrobial therapy have been shown to be non-inferior to longer durations for the management of several infections. However, data on critically ill patients with severe infections by multidrug-resistant Gram-negative bacteria (MDR-GNB) are scarce. In the duratiOn of theraPy in severe infecTIons by MultIdrug-reSistant gram-nEgative bacteria (OPTIMISE) trial, we assessed the non-inferiority of 7-day versus 14-day antimicrobial therapy for patients with intensive care unit (ICU)-acquired severe infections by MDR-GNB. This was a randomised multicenter, open-label, parallel controlled, non-inferiority trial. Adult patients with severe infections by MDR-GNB initiated ≥ 48 h of ICU admission were eligible if they were hemodynamically stable and without fever > 48 h on the 7th day of appropriate antimicrobial therapy. Patients were 1:1 randomised to discontinue antimicrobial therapy on the 7th (± 1) day or to continue for a total of 14 (± 1) days. The primary outcome was clinical failure, defined as death or relapse of infection within 28 days of randomisation. An upper edge of the two-tailed 95% confidence interval (CI) of the delta between the clinical failure rate in the 7- and the 14-day lower than 10% in both intention-to-treat (ITT) and per protocol (PP) analyses was set as the non-inferiority criteria. A total of 106 patients composed the ITT population: 59 and 47 allocated to 7- and 14-day groups, respectively. The PP population included 75 patients: 47 and 28 in the 7- and 14-day groups, respectively. Clinical failure occurred in 42.4% and 44.7% of the ITT population in 7- and 14-day groups, respectively, (risk difference (RD) − 2.3, 95%CI − 21.3 to 16.7), and in 46.8% and 50.0% of the PP population in 7- and 14-day groups, respectively (RD − 3.2, 95%CI − 26.6 to 20.2). Most infections were of the respiratory tract (73/68.9%) and caused by carbapenem-resistant Enterobacterales (42/39.6%). The study was interrupted before reaching planned sample size due to low recruitment rate. The OPTIMISE trial could not determine the non-inferiority of 7-day compared to 14-day therapy for severe infections caused by MDR-GNB due to early termination related to the low recruitment rate. Trial registration: NCT05210387 on January 13, 2022.
- Open Access
- 16 December 2023
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 13 (1) , 237-250
A Randomized, Open-Label, Non-inferiority Clinical Trial Assessing 7 Versus 14 Days of Antimicrobial Therapy for Severe Multidrug-Resistant Gram-Negative Bacterial Infections: The OPTIMISE Trial Protocol
Introduction Shorter courses of antimicrobials have been shown to be non-inferior to longer, “traditional” duration of therapies, including for some severe healthcare-associated infections, with a few exceptions. However, evidence is lacking regarding shorter regimes against severe infections by multidrug-resistant Gram-negative bacteria (MDR-GNB), which are often caused by distinct strains and commonly treated with second-line antimicrobials. In the duratiOn of theraPy in severe infecTIons by MultIdrug-reSistant gram-nEgative bacteria (OPTIMISE) trial, we aim to assess the non-inferiority of 7-day versus 14-day antimicrobial therapy in critically ill patients with severe infections caused by MDR-GNB. Methods This is a randomized, multicenter, open-label, parallel controlled trial to assess the non-inferiority of 7-day versus 14-day of adequate antimicrobial therapy for intensive care unit (ICU)-acquired severe infections by MDR-GNB. Adult patients with severe infections by MDR-GNB initiated after 48 h of ICU admission are screened for eligibility. Patients are eligible if they proved to be hemodynamically stable and without fever for at least 48 h on the 7th day of adequate antimicrobial therapy. After consenting, patients are 1:1 randomized to discontinue antimicrobial therapy on the 7th (± 1) day or to continue for a total of 14th (± 1) days. Planned Outcomes The primary outcome is treatment failure, defined as death or relapse of infection within 28 days after randomization. Non-inferiority will be achieved if the upper edge of the two-tailed 95% confidence interval of the difference between the clinical failure rate in the 7-day and the 14-day group is not higher than 10%. Conclusion The OPTIMISE trial is the first randomized controlled trial specifically designed to assess the duration of antimicrobial therapy in patients with severe infections by MDR-GNB. Trial Registration ClinicalTrials.gov, NCT05210387. Registered on 27 January 2022. Seven Versus 14 Days of Antibiotic Therapy for Multidrug-resistant Gram-negative Bacilli Infections (OPTIMISE).
- 16 December 2023
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 13 (1) , 237-250
Open AccessA Randomized, Open-Label, Non-inferiority Clinical Trial Assessing 7 Versus 14 Days of Antimicrobial Therapy for Severe Multidrug-Resistant Gram-Negative Bacterial Infections: The OPTIMISE Trial Protocol
Introduction Shorter courses of antimicrobials have been shown to be non-inferior to longer, “traditional” duration of therapies, including for some severe healthcare-associated infections, with a few exceptions. However, evidence is lacking regarding shorter regimes against severe infections by multidrug-resistant Gram-negative bacteria (MDR-GNB), which are often caused by distinct strains and commonly treated with second-line antimicrobials. In the duratiOn of theraPy in severe infecTIons by MultIdrug-reSistant gram-nEgative bacteria (OPTIMISE) trial, we aim to assess the non-inferiority of 7-day versus 14-day antimicrobial therapy in critically ill patients with severe infections caused by MDR-GNB. Methods This is a randomized, multicenter, open-label, parallel controlled trial to assess the non-inferiority of 7-day versus 14-day of adequate antimicrobial therapy for intensive care unit (ICU)-acquired severe infections by MDR-GNB. Adult patients with severe infections by MDR-GNB initiated after 48 h of ICU admission are screened for eligibility. Patients are eligible if they proved to be hemodynamically stable and without fever for at least 48 h on the 7th day of adequate antimicrobial therapy. After consenting, patients are 1:1 randomized to discontinue antimicrobial therapy on the 7th (± 1) day or to continue for a total of 14th (± 1) days. Planned Outcomes The primary outcome is treatment failure, defined as death or relapse of infection within 28 days after randomization. Non-inferiority will be achieved if the upper edge of the two-tailed 95% confidence interval of the difference between the clinical failure rate in the 7-day and the 14-day group is not higher than 10%. Conclusion The OPTIMISE trial is the first randomized controlled trial specifically designed to assess the duration of antimicrobial therapy in patients with severe infections by MDR-GNB. Trial Registration ClinicalTrials.gov, NCT05210387. Registered on 27 January 2022. Seven Versus 14 Days of Antibiotic Therapy for Multidrug-resistant Gram-negative Bacilli Infections (OPTIMISE).
- Open Access
- 3 August 2023
- Published by Universidade de São Paulo. Agência de Bibliotecas e Coleções Digitais in Revista de Direito Sanitário
- Vol. 23 (1) , e0003
O retrato da judicialização nas demandas judiciais de saúde propostas pela Defensoria Pública da União no Município de Porto Alegre/RS
This study aimed to characterize the judicialization of health in the performance of the Union Public Defender, in the city of Porto Alegre, state of Rio Grande do Sul, from January to December 2018. The guiding premises for this study were the identification of the main demands met and the socioeconomic variables of the claimants – gender, race / color, age, income, education – from the perspective of public health. The research is relevant because judicialization of health has occupied a prominent place in the volume of claims that reach the service provided by the Judiciary. This situation requires attention from health system managers as the profile of claims that are processed and granted in this area can serve for analyzing and updating policies. To this end, a quantitative and analytical methodological strategy was used. The data were collected from the Information System of the Porto Alegre Unit of the Union Public Defender. The results showed that the institution analyzed needs to improve the identification of the socioeconomic variables of the claimants and that the main demand judicialized by the Union Public Defender was for high-cost medications. It was concluded that judicialization of health can reveal itself sometimes as either a space for the realization of social rights, or sometimes as a deviation from the democratic profile of access to care recommended by the Brazilian Public Health System.
- 3 August 2023
- Published by Universidade de São Paulo. Agência de Bibliotecas e Coleções Digitais in Revista de Direito Sanitário
- Vol. 23 (1) , e0003
Open AccessO retrato da judicialização nas demandas judiciais de saúde propostas pela Defensoria Pública da União no Município de Porto Alegre/RS
This study aimed to characterize the judicialization of health in the performance of the Union Public Defender, in the city of Porto Alegre, state of Rio Grande do Sul, from January to December 2018. The guiding premises for this study were the identification of the main demands met and the socioeconomic variables of the claimants – gender, race / color, age, income, education – from the perspective of public health. The research is relevant because judicialization of health has occupied a prominent place in the volume of claims that reach the service provided by the Judiciary. This situation requires attention from health system managers as the profile of claims that are processed and granted in this area can serve for analyzing and updating policies. To this end, a quantitative and analytical methodological strategy was used. The data were collected from the Information System of the Porto Alegre Unit of the Union Public Defender. The results showed that the institution analyzed needs to improve the identification of the socioeconomic variables of the claimants and that the main demand judicialized by the Union Public Defender was for high-cost medications. It was concluded that judicialization of health can reveal itself sometimes as either a space for the realization of social rights, or sometimes as a deviation from the democratic profile of access to care recommended by the Brazilian Public Health System.
- Open Access
- 17 April 2022
- Published by Research, Society and Development in Research, Society and Development
- Vol. 11 (6)
A cross-sectional study of the COVID-19 pandemic impacts among Brazilian sexual and gender minorities
The COVID-19 pandemic exerted major impacts on the entire population, but some groups such as sexual and gender minorities have been disproportionately affected. Therefore, we aim at assessing the impacts on the social life and mental health of Brazilian sexual and gender minorities during the COVID-19 pandemic. This is a cross-sectional nationwide study conducted between September and October 2020. Participants were recruited through convenience sampling (snowball), being invited to answer an online questionnaire. The participants were invited to participate by social networks and websites directed to the LGBT+ population over 18 years old. This study included 659 sexual and gender minorities from all five Brazilian regions. The main impacts caused by the COVID-19 pandemic reported by the participants were anxiety (73.5%), stress (71%), loneliness (59.6%), sleep pattern changes (69%) and income reduction (36.9%). Participants with low educational level presented higher income reduction than participants with high educational level (0.61, 95% CI 0.48-0.77) and high income (0.46, 95% CI 0.34-0.62). Low income (1.14, 95% CI 1.03-1.26) and being lesbian (1.13, 95% CI 1.01-1.26) are related to changes in sleep patterns. Totally isolated participants presented high stress rates. The LGBT+ population presented high economic and emotional impacts during COVID-19 pandemic. The results of this study highlight the need for heath public policies directed for sexual and gender minorities.
- 17 April 2022
- Published by Research, Society and Development in Research, Society and Development
- Vol. 11 (6)
Open AccessA cross-sectional study of the COVID-19 pandemic impacts among Brazilian sexual and gender minorities
The COVID-19 pandemic exerted major impacts on the entire population, but some groups such as sexual and gender minorities have been disproportionately affected. Therefore, we aim at assessing the impacts on the social life and mental health of Brazilian sexual and gender minorities during the COVID-19 pandemic. This is a cross-sectional nationwide study conducted between September and October 2020. Participants were recruited through convenience sampling (snowball), being invited to answer an online questionnaire. The participants were invited to participate by social networks and websites directed to the LGBT+ population over 18 years old. This study included 659 sexual and gender minorities from all five Brazilian regions. The main impacts caused by the COVID-19 pandemic reported by the participants were anxiety (73.5%), stress (71%), loneliness (59.6%), sleep pattern changes (69%) and income reduction (36.9%). Participants with low educational level presented higher income reduction than participants with high educational level (0.61, 95% CI 0.48-0.77) and high income (0.46, 95% CI 0.34-0.62). Low income (1.14, 95% CI 1.03-1.26) and being lesbian (1.13, 95% CI 1.01-1.26) are related to changes in sleep patterns. Totally isolated participants presented high stress rates. The LGBT+ population presented high economic and emotional impacts during COVID-19 pandemic. The results of this study highlight the need for heath public policies directed for sexual and gender minorities.
- 1 February 2021
- Published by SAGE Publications in American Journal of Health Promotion
- Vol. 35 (6) , 845-852
Health Promotion Practices and Michel Foucault: A Scoping Review
Objective: To analyze Health Promotion (HP) practices in different settings worldwide, presented in studies that employed the Foucauldian framework. Data Source: Scoping review performed on LILACS, MEDLINE, IBECS, BDENF, SciELO, CINAHL, Embase, Web of Science, and Scopus databases. Study Inclusion and Exclusion Criteria: We included original articles, review articles, reflection articles, and case studies published in English, Portuguese, and Spanish, which addressed HP practices, analyzed using the Foucauldian framework. Data Synthesis: In the numerical synthesis, the characteristics of the included studies were described: number of studies, types of method, year of publication, characteristics of the study population, origin countries, and the HP practices addressed in the articles. The thematic synthesis was organized according to the nature of the HP practices presented and the Foucauldian analysis matrix used. Results: The review covered 34 studies, published between 2006 and 2019, whose analysis resulted in 2 thematic synthesis: 1) HP as a biopolitical strategy in the neoliberal context; 2) HP as an expression of resistance and counter-conduct, presenting tensions, struggles, and power games. Conclusion: The field of HP mostly consists of governmentality practices that reinforce the neoliberal health perspective. Some practices show resistance and counter-conduct in the face of governmentality practices, which explains the power relationships in the field of HP.
- 1 February 2021
- Published by SAGE Publications in American Journal of Health Promotion
- Vol. 35 (6) , 845-852
Health Promotion Practices and Michel Foucault: A Scoping Review
Objective: To analyze Health Promotion (HP) practices in different settings worldwide, presented in studies that employed the Foucauldian framework. Data Source: Scoping review performed on LILACS, MEDLINE, IBECS, BDENF, SciELO, CINAHL, Embase, Web of Science, and Scopus databases. Study Inclusion and Exclusion Criteria: We included original articles, review articles, reflection articles, and case studies published in English, Portuguese, and Spanish, which addressed HP practices, analyzed using the Foucauldian framework. Data Synthesis: In the numerical synthesis, the characteristics of the included studies were described: number of studies, types of method, year of publication, characteristics of the study population, origin countries, and the HP practices addressed in the articles. The thematic synthesis was organized according to the nature of the HP practices presented and the Foucauldian analysis matrix used. Results: The review covered 34 studies, published between 2006 and 2019, whose analysis resulted in 2 thematic synthesis: 1) HP as a biopolitical strategy in the neoliberal context; 2) HP as an expression of resistance and counter-conduct, presenting tensions, struggles, and power games. Conclusion: The field of HP mostly consists of governmentality practices that reinforce the neoliberal health perspective. Some practices show resistance and counter-conduct in the face of governmentality practices, which explains the power relationships in the field of HP.
- Open Access
- 1 January 2021
- Published by Even3
- p. 68-87
Promoção da Saúde frente à Pandemia de Covid-19: análise das estratégias utilizadas em países selecionados
Esta publicação, a 6ª da série LEIASS (Linha Editorial Internacional de Apoio aos Sistemas de Saúde), é fruto dos esforços conjuntos do Conselho Nacional de Secretários de Saúde do Brasil (CONASS) e do Instituto de Higiene e Medicina Tropical da Universidade Nova de Lisboa em reunir artigos de destacados autores, de diferentes países, sobre o […]
- 1 January 2021
- Published by Even3
- p. 68-87
Open AccessPromoção da Saúde frente à Pandemia de Covid-19: análise das estratégias utilizadas em países selecionados
Esta publicação, a 6ª da série LEIASS (Linha Editorial Internacional de Apoio aos Sistemas de Saúde), é fruto dos esforços conjuntos do Conselho Nacional de Secretários de Saúde do Brasil (CONASS) e do Instituto de Higiene e Medicina Tropical da Universidade Nova de Lisboa em reunir artigos de destacados autores, de diferentes países, sobre o […]